Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: CBLB

Gene summary for CBLB

Gene summary.

Gene information	Species	Human
	Gene symbol	CBLB
	Gene ID	868
	Gene name	Cbl proto-oncogene B
	Gene Alias	Cbl-b
	Cytomap	3q13.11
	Gene Type	protein-coding
	GO ID	GO:0001775
	UniProtAcc	Q13191

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
868	CBLB	CCI_2	Human	Cervix	CC	1.59e-04	7.81e-01	0.5249
868	CBLB	CCI_3	Human	Cervix	CC	6.32e-16	9.84e-01	0.516
868	CBLB	HTA11_5212_2000001011	Human	Colorectum	AD	5.04e-03	-6.00e-01	-0.2061
868	CBLB	HTA11_866_3004761011	Human	Colorectum	AD	1.65e-03	-3.32e-01	0.096
868	CBLB	HTA11_8622_2000001021	Human	Colorectum	SER	3.64e-02	-4.91e-01	0.0528
868	CBLB	HTA11_99999974143_84620	Human	Colorectum	MSS	4.40e-23	-6.20e-01	0.3005
868	CBLB	A002-C-010	Human	Colorectum	FAP	2.20e-03	1.31e-01	0.242
868	CBLB	A001-C-207	Human	Colorectum	FAP	8.74e-04	1.41e-01	0.1278
868	CBLB	A015-C-203	Human	Colorectum	FAP	1.50e-27	-2.52e-01	-0.1294
868	CBLB	A015-C-204	Human	Colorectum	FAP	1.34e-06	-2.13e-01	-0.0228
868	CBLB	A014-C-040	Human	Colorectum	FAP	5.84e-05	-2.28e-01	-0.1184
868	CBLB	A002-C-201	Human	Colorectum	FAP	3.42e-14	-2.35e-01	0.0324
868	CBLB	A002-C-203	Human	Colorectum	FAP	3.45e-03	-1.10e-03	0.2786
868	CBLB	A001-C-119	Human	Colorectum	FAP	6.83e-07	-4.03e-01	-0.1557
868	CBLB	A001-C-108	Human	Colorectum	FAP	4.53e-16	-2.54e-01	-0.0272
868	CBLB	A002-C-021	Human	Colorectum	FAP	4.58e-03	3.65e-01	0.1171
868	CBLB	A002-C-205	Human	Colorectum	FAP	7.28e-25	-3.41e-01	-0.1236
868	CBLB	A001-C-104	Human	Colorectum	FAP	1.95e-02	-7.98e-02	0.0184
868	CBLB	A015-C-006	Human	Colorectum	FAP	2.64e-18	-5.08e-01	-0.0994
868	CBLB	A015-C-106	Human	Colorectum	FAP	1.13e-10	-2.41e-01	-0.0511

Page: 1 2 3 4 5 6 7 8 9 10

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Cervix		CC: Cervix cancer
		HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions
		N_HPV: HPV-infected normal cervix
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Endometrium		AEH: Atypical endometrial hyperplasia
		EEC: Endometrioid Cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
GC		CAG: Chronic atrophic gastritis
		CAG with IM: Chronic atrophic gastritis with intestinal metaplasia
		CSG: Chronic superficial gastritis
		GC: Gastric cancer
		SIM: Severe intestinal metaplasia
		WIM: Wild intestinal metaplasia
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Lung		AAH: Atypical adenomatous hyperplasia
		AIS: Adenocarcinoma in situ
		IAC: Invasive lung adenocarcinoma
		MIA: Minimally invasive adenocarcinoma
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:0050868	Cervix	CC	negative regulation of T cell activation	31/2311	122/18723	5.81e-05	8.46e-04	31
GO:00329435	Cervix	CC	mononuclear cell proliferation	59/2311	291/18723	7.51e-05	1.03e-03	59
GO:00022533	Cervix	CC	activation of immune response	72/2311	375/18723	8.26e-05	1.11e-03	72
GO:00336739	Cervix	CC	negative regulation of kinase activity	50/2311	237/18723	9.22e-05	1.21e-03	50
GO:00420586	Cervix	CC	regulation of epidermal growth factor receptor signaling pathway	21/2311	73/18723	1.36e-04	1.67e-03	21
GO:19011846	Cervix	CC	regulation of ERBB signaling pathway	22/2311	79/18723	1.61e-04	1.93e-03	22
GO:1903038	Cervix	CC	negative regulation of leukocyte cell-cell adhesion	33/2311	141/18723	1.90e-04	2.21e-03	33
GO:00433939	Cervix	CC	regulation of protein binding	42/2311	196/18723	2.27e-04	2.55e-03	42
GO:0050866	Cervix	CC	negative regulation of cell activation	44/2311	210/18723	2.76e-04	3.02e-03	44
GO:0046640	Cervix	CC	regulation of alpha-beta T cell proliferation	12/2311	35/18723	6.55e-04	6.05e-03	12
GO:0002768	Cervix	CC	immune response-regulating cell surface receptor signaling pathway	59/2311	315/18723	6.64e-04	6.11e-03	59
GO:00466342	Cervix	CC	regulation of alpha-beta T cell activation	25/2311	104/18723	7.13e-04	6.46e-03	25
GO:00508603	Cervix	CC	negative regulation of T cell receptor signaling pathway	9/2311	22/18723	7.19e-04	6.49e-03	9
GO:0046633	Cervix	CC	alpha-beta T cell proliferation	12/2311	38/18723	1.49e-03	1.16e-02	12
GO:00508524	Cervix	CC	T cell receptor signaling pathway	27/2311	123/18723	1.93e-03	1.42e-02	27
GO:00071761	Cervix	CC	regulation of epidermal growth factor-activated receptor activity	10/2311	30/18723	2.33e-03	1.66e-02	10
GO:0070664	Cervix	CC	negative regulation of leukocyte proliferation	21/2311	90/18723	2.71e-03	1.85e-02	21
GO:00508562	Cervix	CC	regulation of T cell receptor signaling pathway	12/2311	41/18723	3.06e-03	2.01e-02	12
GO:0050854	Cervix	CC	regulation of antigen receptor-mediated signaling pathway	16/2311	63/18723	3.42e-03	2.22e-02	16
GO:19011857	Cervix	CC	negative regulation of ERBB signaling pathway	10/2311	32/18723	3.96e-03	2.48e-02	10

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48

Enriched KEGG pathways.

Pathway ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	qvalue	Count
hsa0412014	Cervix	CC	Ubiquitin mediated proteolysis	49/1267	142/8465	4.26e-09	7.68e-08	4.54e-08	49
hsa0414418	Cervix	CC	Endocytosis	64/1267	251/8465	6.97e-06	6.10e-05	3.61e-05	64
hsa0401210	Cervix	CC	ErbB signaling pathway	28/1267	85/8465	2.40e-05	1.82e-04	1.08e-04	28
hsa046254	Cervix	CC	C-type lectin receptor signaling pathway	25/1267	104/8465	9.52e-03	2.94e-02	1.74e-02	25
hsa046604	Cervix	CC	T cell receptor signaling pathway	25/1267	104/8465	9.52e-03	2.94e-02	1.74e-02	25
hsa0412015	Cervix	CC	Ubiquitin mediated proteolysis	49/1267	142/8465	4.26e-09	7.68e-08	4.54e-08	49
hsa0414419	Cervix	CC	Endocytosis	64/1267	251/8465	6.97e-06	6.10e-05	3.61e-05	64
hsa0401213	Cervix	CC	ErbB signaling pathway	28/1267	85/8465	2.40e-05	1.82e-04	1.08e-04	28
hsa0462511	Cervix	CC	C-type lectin receptor signaling pathway	25/1267	104/8465	9.52e-03	2.94e-02	1.74e-02	25
hsa0466011	Cervix	CC	T cell receptor signaling pathway	25/1267	104/8465	9.52e-03	2.94e-02	1.74e-02	25
hsa04012	Colorectum	AD	ErbB signaling pathway	31/2092	85/8465	1.02e-02	3.91e-02	2.50e-02	31
hsa040121	Colorectum	AD	ErbB signaling pathway	31/2092	85/8465	1.02e-02	3.91e-02	2.50e-02	31
hsa041442	Colorectum	SER	Endocytosis	81/1580	251/8465	1.14e-07	2.36e-06	1.71e-06	81
hsa041202	Colorectum	SER	Ubiquitin mediated proteolysis	39/1580	142/8465	6.18e-03	3.66e-02	2.66e-02	39
hsa041443	Colorectum	SER	Endocytosis	81/1580	251/8465	1.14e-07	2.36e-06	1.71e-06	81
hsa041203	Colorectum	SER	Ubiquitin mediated proteolysis	39/1580	142/8465	6.18e-03	3.66e-02	2.66e-02	39
hsa041444	Colorectum	MSS	Endocytosis	102/1875	251/8465	1.85e-11	4.43e-10	2.71e-10	102
hsa041204	Colorectum	MSS	Ubiquitin mediated proteolysis	55/1875	142/8465	5.02e-06	6.00e-05	3.68e-05	55
hsa040122	Colorectum	MSS	ErbB signaling pathway	30/1875	85/8465	3.73e-03	1.67e-02	1.02e-02	30
hsa041445	Colorectum	MSS	Endocytosis	102/1875	251/8465	1.85e-11	4.43e-10	2.71e-10	102

Page: 1 2 3 4 5 6 7 8 9

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

CBLB

SNV

Missense_Mutation

c.422G>A

p.Arg141Gln

p.R141Q

Q13191

protein_coding

deleterious(0.01)

probably_damaging(0.997)

TCGA-A7-A0CJ-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

cytoxan

CBLB

SNV

Missense_Mutation

c.1753N>A

p.Asp585Asn

p.D585N

Q13191

protein_coding

tolerated_low_confidence(0.06)

benign(0.001)

TCGA-A8-A09Q-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Hormone Therapy

anastrozole

CBLB

SNV

Missense_Mutation

rs748390313

c.2200N>T

p.Arg734Trp

p.R734W

Q13191

protein_coding

tolerated_low_confidence(0.06)

probably_damaging(0.936)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

CBLB

SNV

Missense_Mutation

novel

c.68N>G

p.Leu23Trp

p.L23W

Q13191

protein_coding

deleterious_low_confidence(0)

probably_damaging(0.994)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

CBLB

SNV

Missense_Mutation

c.229N>G

p.Ile77Val

p.I77V

Q13191

protein_coding

deleterious(0.02)

possibly_damaging(0.876)

TCGA-AO-A03L-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

cyclophosphamide

CBLB

SNV

Missense_Mutation

c.769C>T

p.His257Tyr

p.H257Y

Q13191

protein_coding

deleterious(0)

probably_damaging(1)

TCGA-AR-A251-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

doxorubicin

CBLB

SNV

Missense_Mutation

c.952N>G

p.Gln318Glu

p.Q318E

Q13191

protein_coding

deleterious(0)

possibly_damaging(0.833)

TCGA-B6-A0IK-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Unknown

CBLB

SNV

Missense_Mutation

c.1210G>A

p.Asp404Asn

p.D404N

Q13191

protein_coding

deleterious(0.04)

probably_damaging(0.95)

TCGA-BH-A0B5-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

adriamycin

CBLB

SNV

Missense_Mutation

c.2483C>T

p.Ala828Val

p.A828V

Q13191

protein_coding

tolerated_low_confidence(0.4)

benign(0.116)

TCGA-BH-A0C1-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

adriamycin

CBLB

SNV

Missense_Mutation

c.1073N>G

p.Glu358Gly

p.E358G

Q13191

protein_coding

deleterious(0)

benign(0.241)

TCGA-BH-A0DK-01

Breast

breast invasive carcinoma

Female

<65

I/II

Hormone Therapy

tamoxiphen

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID	Symbol	Category	Interaction Types	Drug Claim Name	Drug Name	PMIDs
868	CBLB	CLINICALLY ACTIONABLE, ENZYME		Fasudil	FASUDIL	26177294
868	CBLB	CLINICALLY ACTIONABLE, ENZYME		Fluorouracil	FLUOROURACIL	24351824

Page: 1